What is it about?
Pharmacotherapy represents a desirable potential therapeutic alternative for patients with obstructive sleep apnoea. This review summarises all available evidence on this topic and identifies future treatment options.
Featured Image
Photo by Vladislav Muslakov on Unsplash
Why is it important?
Obstructive sleep apnoea is a major public health problem. One major limitation of treatment is that continuous positive airway pressure therapy (the main therapy) is not tolerated by a large proportion of users. Thus, pharmacotherapy represents an easily applicable and attractive alternative for the treatment of obstructive sleep apnoea.
Perspectives
There is currently insufficient evidence to recommend any pharmacotherapy for treatment of obstructive sleep apnoea and there are currently no advanced clinical trials on this topic (i.e. phase III trials). However, industry-sponsored trials are now established in this promising field and new substances for the single purpose of treating obstructive sleep apnoea are being developed.
Thomas Gaisl
Read the Original
This page is a summary of: Efficacy of pharmacotherapy for OSA in adults: a systematic review and network meta-analysis, September 2019, European Respiratory Society (ERS),
DOI: 10.1183/13993003.congress-2019.pa4168.
You can read the full text:
Resources
Contributors
The following have contributed to this page
